Centessa Pharmaceuticals (CNTA) on Wednesday filed a registration statement covering the potential sale of its securities from time to time.
The filing covers ordinary shares, American depositary shares, debt securities, warrants, and units.
Net proceeds will be primarily for general corporate purposes, the company said, adding it may also use part of the proceeds to pay interest or principal on debt and/or buy and invest in companies, products and technologies.
Separately, Centessa said Wednesday it has started an underwritten public offering of $150 million of American depositary shares.
The company said it plans to give the underwriters a 30-day option to buy up to an additional $22.5 million of ADSs.
The planned offering is subject to market conditions, and there's no assurance as to whether or when it may be completed, or as to its size or terms, Centessa added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。